CA
NZ
UK
AU
IND
US
…
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
A Nasdaq-listed company, Coya Therapeutics focuses on developing therapeutics, though public disclosures on specific programs are limited. Long-term growth could be driven by clinical progress, regulatory approvals and partnerships to advance and commercialize candidates. Investors may view the company as offering upside tied to pipeline de‑risking while recognizing binary outcomes and extended timelines.
Key risks include clinical or regulatory failure, high cash burn with future financing needs and sparse public information that increases uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -21.22M | -15.60M | -7.26M | -12.24M | -4.89M |
| Net income | -21.23M | -14.88M | -7.99M | -14.68M | -4.87M |
| Selling general administrative | 11.45M | 8.89M | 7.83M | 4.85M | 2.31M |
| Selling and marketing expenses | - | 8876.87M | - | - | - |
| Gross profit | 7.92M | -8.31M | 0.50M | - | - |
| Reconciled depreciation | 0.03M | 0.03M | 0.03M | 0.03M | 0.02M |
| Ebit | -20.27M | -17.22M | -7.36M | -9.81M | -4.87M |
| Ebitda | -20.24M | -17.20M | -7.33M | -9.78M | -4.88M |
| Depreciation and amortization | 0.03M | 0.03M | 0.03M | 0.03M | -0.01M |
| Operating income | -20.27M | -17.25M | -7.90M | -9.81M | -4.87M |
| Other operating expenses | 28.21M | 20.80M | 13.91M | 9.81M | 4.87M |
| Interest expense | - | - | - | 2.43M | 0.02M |
| Tax provision | 0.00M | -0.72M | 0.72M | - | - |
| Net interest income | - | - | - | - | 0.00M |
| Income tax expense | 0.00M | -0.72M | 0.72M | 2.43M | -0.02M |
| Total revenue | 7.95M | 3.55M | 6.00M | 0.00M | 0.00M |
| Total operating expenses | 28.18M | 8.94M | 8.40M | 9.81M | 4.87M |
| Cost of revenue | 0.03M | 11.87M | 5.50M | - | - |
| Total other income expense net | -0.96M | 1.65M | 0.64M | -2.43M | -0.02M |
| Net income from continuing ops | -21.23M | -14.88M | -12.36M | -12.24M | -4.89M |
| Net income applicable to common shares | - | - | - | -12.24M | -4.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 49.95M | 44.35M | 41.27M | 8.40M | 4.79M |
| Other current assets | 3.12M | 5.24M | 1.07M | 1.25M | 0.24M |
| Total liab | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Total stockholder equity | 43.03M | 39.58M | 35.65M | -8.39M | 3.64M |
| Deferred long term liab | - | - | - | 1.12M | 0.09M |
| Other current liab | 3.61M | 1.39M | 2.25M | 2.01M | 0.29M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 8.79M | 8.79M |
| Retained earnings | -61.96M | -40.74M | -25.86M | -17.87M | -5.62M |
| Other assets | - | -44264.12M | - | 1.12M | 0.09M |
| Cash | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total current liabilities | 5.87M | 3.82M | 5.05M | 3.82M | 1.15M |
| Current deferred revenue | 1.20M | 0.85M | 0.92M | - | - |
| Net debt | -46.82M | -38.34M | -32.63M | 7.03M | -4.34M |
| Short term debt | - | - | 0.72M | - | - |
| Short long term debt total | - | - | - | 12.97M | - |
| Other stockholder equity | 104.99M | 80.31M | 61.50M | 0.68M | 0.47M |
| Property plant equipment | - | - | - | 0.09M | 0.12M |
| Total current assets | 49.94M | 44.31M | 41.20M | 7.18M | 4.58M |
| Net tangible assets | - | - | - | -17.19M | -5.15M |
| Short term investments | - | 38301.42M | - | - | - |
| Net receivables | - | 0.73M | 7.50M | - | - |
| Long term debt | - | - | - | 12.97M | - |
| Accounts payable | 1.06M | 1.59M | 1.16M | 1.82M | 0.86M |
| Accumulated other comprehensive income | - | - | -0.01M | - | - |
| Non currrent assets other | - | 38.55M | - | 1.12M | 0.09M |
| Non current assets total | 0.01M | 0.04M | 0.08M | 1.21M | 0.21M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.03M | -0.74M | -0.53M | -0.14M |
| Change to liabilities | - | - | - | 0.85M | 0.67M |
| Total cashflows from investing activities | -1.16M | -0.03M | -0.54M | -0.53M | -0.14M |
| Net borrowings | - | - | 0.00M | 10.47M | 10.47M |
| Total cash from financing activities | 20.39M | 16.03M | 38.43M | 9.36M | -0.34M |
| Change to operating activities | - | - | - | -0.09M | 0.07M |
| Net income | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
| Change in cash | 8.48M | 5.71M | 26.69M | 1.59M | -4.38M |
| Begin period cash flow | 38.34M | 32.63M | 5.93M | 4.34M | 8.72M |
| End period cash flow | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total cash from operating activities | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Issuance of capital stock | 20.35M | 14.00M | 38.34M | - | 0.00M |
| Depreciation | 0.03M | 0.03M | 0.03M | 0.03M | 0.02M |
| Other cashflows from investing activities | -1.16M | -0.03M | -0.54M | - | - |
| Change to account receivables | - | 7.50M | -7.50M | - | - |
| Other cashflows from financing activities | 20.39M | 2.02M | 0.09M | 9.36M | -0.34M |
| Change to netincome | - | - | - | 3.23M | 0.23M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.14M |
| Change in working capital | 3.88M | 1.88M | -4.64M | 0.75M | 0.74M |
| Stock based compensation | 4.29M | 2.66M | 0.87M | 0.21M | 0.23M |
| Other non cash items | 2.29M | 0.03M | 0.54M | 4.02M | - |
| Free cash flow | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics, Inc. Common Stock |
0.17 4.30% |
4.12 | - | - | 13.60 | 2.52 | 8.22 | -6.21 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
5850 San Felipe St., Houston, TX, United States, 77057
800 587 8170
8
| Name | Title | Year Born |
|---|---|---|
| Dr. Howard Berman Ph.D. | Chairman & CEO | 1974 |
| Dr. Fred Grossman D.O., FAPA | President & Chief Medical Officer | 1962 |
| Mr. David S. Snyder | CFO & COO | 1960 |
| Dr. Gregory MacMichael Ph.D. | Chief Technical Officer | 1956 |
| Dr. Michelle Frazier Ph.D. | Senior Vice President of Regulatory Affairs | NA |
| Mr. Aaron Thome Ph.D. | Head of Neuroinflammation Platform | NA |
| Dr. Arun Swaminathan Ph.D. | Chief Business Development Officer | NA |
| Dr. Arun Swaminathan Ph.D. | CEO & Director | 1970 |
| Dr. Fred Grossman D.O., FAPA | President & Chief Medical Officer | 1959 |
| Mr. David S. Snyder M.B.A. | CFO & COO | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...